Excelsior Biopharma (6496) — Cash Flow Reinvestment Rate
Excelsior Biopharma (6496) has a Cash Flow Reinvestment Rate of 6.86x as of June 2025, reinvesting NT$26.07 Million (capex NT$14.44 Million plus investments NT$-11.63 Million) from operating cash flow of NT$3.80 Million. Check Excelsior Biopharma (6496) cash flow quality to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Excelsior Biopharma Cash Flow Reinvestment Rate (2017–2022)
Historical reinvestment intensity for Excelsior Biopharma across 5 annual periods. Explore Excelsior Biopharma (6496) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Annual Cash Flow Reinvestment Rate for Excelsior Biopharma (2017–2022)
Year-by-year capital reinvestment analysis for Excelsior Biopharma. For live market cap and broader valuation context, see Excelsior Biopharma market cap and net worth.
| Year | Reinvestment Rate | Total Reinvested (TWD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 37.88x | NT$207.78 Million | NT$5.49 Million | NT$7.78 Million | ▲ +23704.4% |
| 2021 | 0.16x | NT$8.88 Million | NT$55.82 Million | NT$2.88 Million | ▲ +89.2% |
| 2020 | 0.08x | NT$43.80 Million | NT$520.81 Million | NT$11.62 Million | ▼ -74.3% |
| 2018 | 0.33x | NT$41.51 Million | NT$126.92 Million | NT$9.54 Million | ▲ +524.0% |
| 2017 | 0.05x | NT$18.32 Million | NT$349.47 Million | NT$18.10 Million | — |